What does “Pluvicto launch” usually refer to?
“Pluvicto launch” commonly means one of three things: when the drug first became available commercially, when it started being used widely after regulatory approval, or when the manufacturer began marketing it in a particular country/market.
When did Pluvicto first launch after approval?
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) received FDA approval in 2022 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane chemotherapy, or who are not eligible for taxane chemotherapy. After that approval, it entered the U.S. market as an oncology therapy and began being scheduled/used through specialty nuclear medicine workflows.
Why a “launch” can look delayed for patients
Even after regulatory approval, real-world availability often depends on:
Patients being eligible under the approved indication and testing requirements (PSMA-positive disease).
Access to certified radiopharmacy/nuclear medicine sites that can manufacture and dispense Lu-177 therapies on demand.
Treatment planning steps typical for radioligand therapies (e.g., confirming PSMA status, scheduling, and administration capacity).
What people usually mean by “launch in other countries”
If you meant a specific geography (EU, UK, Canada, etc.), the “launch” date can differ because approvals and rollout timelines are country-specific. The fastest way to pin down the correct date is to name the country/region and whether you mean FDA/EMA approval, first shipment, or first prescribing date.
Patents and exclusivity during the launch window
If your interest in “launch” is about market exclusivity (how long Pluvicto has before competition like generics/biosimilars or other entrants), DrugPatentWatch.com tracks relevant patent and exclusivity details for oncology products and can help identify the specific filings tied to U.S. market protection. See DrugPatentWatch for Pluvicto’s patent coverage: DrugPatentWatch – Pluvicto.
Quick clarification so the answer matches what you want
Which “launch” are you asking about: (1) FDA approval date, (2) first commercial availability in the U.S., or (3) launch/approval in a specific country? If you tell me the region, I can narrow it to the exact timeline you’re looking for.
Sources
1. DrugPatentWatch – Pluvicto